Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries. This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and <keyword id="3219739" type="COMPANY" weightage="20" keywordseo="The-Gates-Foundation">the Gates Foundation</keyword> to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August. The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator sees a need for it. The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of <keyword id="10021049" type="COMPANY" weightage="20" keywordseo="the-gavi-covax-amc">the Gavi COVAX AMC</keyword> mechanism as early as the first half of 2021. "The collaboration further bolsters our fight against Covid-19. Through the avid support of Gavi and the Bill &amp; Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future Covid-19 vaccines to India and low- and middle-income countries in 2021," said Adar Poonawalla, CEO of Serum Institute of India. He added, "At this stage, it is important for governments, <keyword id="758352" type="ORGANIZATION" weightage="20" keywordseo="global-health">global health</keyword> and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that the future vaccines reach the remotest part of the world providing full immunization coverage in a bid to contain the spread of the pandemic." The funding will help accelerate the manufacturing by SII for candidate vaccines licensed from <keyword id="6409874" type="COMPANY" weightage="20" keywordseo="astrazeneca">AstraZeneca</keyword> and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification. The vaccines will have a ceiling price of US$3 per dose, a price enabled by investments made by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill and Melinda Gates Foundation and SII. "This is vaccine manufacturing for <keyword id="10021050" type="LOCATION" weightage="20" keywordseo="the-global-south">the Global South</keyword>, by the Global South, helping us to ensure no country is left behind when it comes to access to a Covid-19 vaccine," said Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance. "The momentum behind our effort to ensure global, equitable access to Covid-19 vaccines is really building. Last week, we were able to announce the historic number of countries that are now signed up to the COVAX Facility, today we can announce further doses of safe, effective vaccines that will be reserved specifically for low- and middle-income countries. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines; this collaboration brings us another step closer to achieving this goal." The Gavi COVAX AMC, which is currently seeking at least US$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. The Gavi Board has agreed upon the final list of 92 countries that will be supported by the Gavi COVAX AMC. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi COVAX AMC. These countries align with SII's licensing agreements with the two partners. The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, CEPI and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them. Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar. Under the COVAX umbrella, Gavi is coordinating the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of Covid-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand. So far 73 higher-income economies have formally committed to join the Facility, in addition to the 92 low- and middle-income economies that are eligible for support from the Gavi COVAX AMC. The Bill &amp; Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further US$150 million to Gavi, bringing the total funding provided through this collaboration to US$300 million. This will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for India and low- and middle-income countries via Gavi's COVAX AMC. The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will commit an additional 300 million doses of AstraZeneca's candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help assure access to early doses for the most vulnerable on a truly global scale. <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/icmr-now-flags-chances-of-chinese-cat-que-virus-in-india/articleshow/78381490.cms">ICMR now flags chances of Chinese 'Cat Que Virus' in India</a>

Serum Institute to manufacture 200 million doses of COVID-19 vaccine

New Delhi, Sep 29 (IANS) A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries. This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August. The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator sees a need for it. The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021. "The collaboration further bolsters our fight against Covid-19. Through the avid support of Gavi and the Bill &amp; Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future Covid-19 vaccines to India and low- and middle-income countries in 2021," said Adar Poonawalla, CEO of Serum Institute of India. He added, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that the future vaccines reach the remotest part of the world providing full immunization coverage in a bid to contain the spread of the pandemic." The funding will help accelerate the manufacturing by SII for candidate vaccines licensed from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification. The vaccines will have a ceiling price of US$3 per dose, a price enabled by investments made by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill and Melinda Gates Foundation and SII. "This is vaccine manufacturing for the Global South, by the Global South, helping us to ensure no country is left behind when it comes to access to a Covid-19 vaccine," said Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance. "The momentum behind our effort to ensure global, equitable access to Covid-19 vaccines is really building. Last week, we were able to announce the historic number of countries that are now signed up to the COVAX Facility, today we can announce further doses of safe, effective vaccines that will be reserved specifically for low- and middle-income countries. No country, rich or poor, should be left at the back of the queue when it comes to Covid-19 vaccines; this collaboration brings us another step closer to achieving this goal." The Gavi COVAX AMC, which is currently seeking at least US$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. The Gavi Board has agreed upon the final list of 92 countries that will be supported by the Gavi COVAX AMC. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 61 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the Gavi COVAX AMC. These countries align with SII's licensing agreements with the two partners. The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, CEPI and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them. Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar. Under the COVAX umbrella, Gavi is coordinating the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of Covid-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand. So far 73 higher-income economies have formally committed to join the Facility, in addition to the 92 low- and middle-income economies that are eligible for support from the Gavi COVAX AMC. The Bill &amp; Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further US$150 million to Gavi, bringing the total funding provided through this collaboration to US$300 million. This will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for India and low- and middle-income countries via Gavi's COVAX AMC. The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will commit an additional 300 million doses of AstraZeneca's candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help assure access to early doses for the most vulnerable on a truly global scale. --IANS aka/dpb

Serum Institute to manufacture 200mn doses of Covid-19 vaccine

<ul><li><keyword id="95879" type="ORGANIZATION" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword> (SII) to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries (LMICs).</li><li>The collaboration will provide upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO prequalification, doses can be produced at scale for distribution to India and LMIC as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.</li><li>The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification.</li></ul> Serum Institute of India (SII), the worlds largest vaccine manufacturer by volume, has entered into a new landmark partnership with Gavi, The Vaccine Alliance and the Bill &amp; Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries (LMICs). The collaboration will provide upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO prequalification, doses can be produced at scale for distribution to India and LMIC as part of the Gavi COVAX AMC mechanism as early as the first half of 2021. The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification. SII has set an affordable ceiling price of $3 per dose. The arrangement also provides an option to secure additional doses if the vaccines pillar of the ACT Accelerator sees a need for it. "In an attempt to make our fight against COVID-19 stronger and all-embracing; SII has partnered with Gavi and the Bill &amp; Melinda Gates Foundation to advance the manufacturing and delivery of up to 100 million doses of future COVID vaccines for India and low and middle income countries in 2021," said Adar Poonawalla, CEO of Serum Institute of India. "The rampant spread of the virus has rendered the entire world in an unimaginable halt of uncertainty. And to ensure maximum immunization coverage and contain the pandemic, it is important to make sure that the most remote and poorest countries of the world have access to affordable cure and preventive measures. Through this association, we seek to ramp up our constant efforts to save the lives of millions of people from this dreadful disease." SII shares a long history of successful partnerships with Gavi and pharmaceutical companies to manufacture vaccines that protect against meningitis, severe diarrhoea, pneumonia and measles. This collaboration further underscores India's proven-track record in developing safe and quality vaccines. Renu Swarup, Secretary, Department of Biotechnology said, "India has a proven track record of manufacturing safe and cost-effective vaccines not only for India, but for the world. Over the last decade, Government of India has encouraged innovation, and supported the Indian vaccine industry to manufacture high quality, affordable indigenous tools and products to benefit India and the world. We are very happy to see SII enter this global partnership to respond to the global health crisis posed by Covid-19." Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), commented, "India's has demonstrated consistent capability in delivering on low-cost and high-quality medical research, while also maintaining technical and scientific rigour. ICMR is deeply supportive of our cutting edge vaccine research and manufacturing prowess, of which SII is one prominent example. This partnership signifies yet another step in India's efforts to bolster the fight against this global pandemic." The Gavi Covax AMC, which is currently seeking at least US$ 2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. Last week the Gavi Board agreed the final list of 92 countries that will be supported by the AMC. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 57 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the AMC The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them. Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar. Under the COVAX umbrella, Gavi is leading the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand. The Facility is reinforced by the AMC which provides funding for vaccines for lower income countries. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/the-beirut-explosion-created-a-huge-mushroom-cloud-and-visible-blast-wave-but-nuclear-weapons-experts-say-it-wasnt-an-atomic-blast-heres-why-/articleshow/77362144.cms">The Beirut explosion created a huge mushroom cloud and visible blast wave, but nuclear weapons experts say it wasn't an atomic bomb. Here's why.</a> <a href="https://www.businessinsider.in/business/startups/news/microsoft-for-startups-lathika-pai-says-entrepreneurs-pitching-for-investments-need-to-have-this-one-question-answered-in-their-pitch-decks/articleshow/77352935.cms">Microsoft for Startups’ Lathika Pai says entrepreneurs pitching for investments need to have this one question answered in their pitch decks</a> <a href="https://www.businessinsider.in/careers/news/linkedin-tcs-disney-hotstar-zee-and-other-companies-hiring-right-now-in-india/slidelist/77352775.cms">LinkedIn, TCS, Disney+ Hotstar, Zee and other companies hiring right now in India</a>

Serum Institute of India to produce 100 million doses of COVID-19 vaccine for less than ₹250 a dose

United Nations, Sep 7 (IANS) In what could possibly be the world's largest and fastest ever procurement and supply of vaccines, the United Nations Children's Fund (Unicef) has said that it will lead efforts for Covid-19 vaccine supply for 92 low and lower middle-income countries. These efforts will be part of the Covid-19 Vaccine Global Access Facility (Covax Facility) plans led by Gavi, the Vaccine Alliance. Vaccine purchases for these countries will be supported by the mechanism through the Gavi Advance Market Commitment for Covid-19 Vaccines (Gavi Covax AMC) as well as a buffer stockpile for humanitarian emergencies, Unicef said. In addition, the UN agency will also serve as the procurement coordinator to support procurement by 80 higher-income economies, which have expressed their intent to participate in the Covax Facility and would finance the vaccines from their own public finance budgets. Unicef will undertake these efforts in close collaboration with the WHO, Gavi, Coalition for Epidemic Preparedness Innovations (CEPI), Pan American Health Organization (PAHO), World Bank, the Bill and Melinda Gates Foundation and other partners. The Covax Facility is open to all countries to ensure that no country is left without access to a future Covid-19 vaccine. "This is an all-hands on deck partnership between governments, manufacturers and multilateral partners to continue the high stakes fight against the Covid-19 pandemic," Henrietta Fore, Unicef Executive Director, said in a statement. "In our collective pursuit of a vaccine, Unicef is leveraging its unique strengths in vaccine supply to make sure that all countries have safe, fast and equitable access to the initial doses when they are available," the statement read. Unicef is the largest single vaccine buyer in the world, procuring more than two billion doses of vaccines annually for routine immunisation and outbreak response on behalf of nearly 100 countries. In response to an expression of interest that Unicef issued in June on behalf of the Covax Facility, 28 manufacturers with production facilities in 10 countries shared their annual production plans for Covid-19 vaccines through 2023. According to the timelines indicated by the manufacturers, the span from development to production could be one of the fastest scientific and manufacturing leaps in history, the organisation said. A Unicef market assessment, developed by compiling information submitted by the vaccine manufacturers along with publicly available data, revealed that manufacturers are willing to collectively produce unprecedented quantities of vaccines over the coming one to two years. However, manufacturers signalled that investments to support such large-scale production of doses would be highly dependent on, among other things, whether clinical trials are successful, advance purchase agreements are put in place, funding is confirmed, and regulatory and registration pathways are streamlined. --IANS gb/arm

Unicef to lead global supply of Covid-19 vaccine

New Delhi, <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword> is the <keyword id="10383107" type="UNKNOWN" weightage="20" keywordseo="largest-buyer">largest buyer</keyword> of COVID-19 vaccines in the world with 1.6 billion doses, according to a <keyword id="10241048" type="UNKNOWN" weightage="20" keywordseo="global-analysis">global analysis</keyword>, a number some scientists say could cover 800 million people, or 60 per cent of its population, and will be enough to develop 'herd immunity'. India has purchased 500 million doses of the Oxford University-AstraZeneca <keyword id="24209" type="PERSON" weightage="20" keywordseo="vaccine">vaccine</keyword> candidate, one billion from the US company Novavax and 100 million doses of the Sputnik V candidate from Russia's Gamaleya Research Institute, according to the US-based Duke University Global Health Innovation Center. The 'Launch and Scale Speedometer' analysis, which is updated every two weeks, shows India has confirmed 1.6 billion doses of three vaccines as of November 30 while the US and the EU have purchased doses of six candidates. According to the analysis, India is the top COVID-19 vaccine buyer followed by the European Union which has confirmed 1.58 billion doses and the US, the worst affected country so far, that has managed to purchase just over a billion doses. As countries strategise to secure more shots to protect their populations against the novel <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> infection, Duke University has released a new global assessment of purchasing agreements for COVID-19 vaccines, even before any candidates are in the market. "Countries with manufacturing capacity, such as India and Brazil, have been successful in negotiating large advance market commitments with leading vaccine candidates as part of the manufacturing agreements," the Duke researchers noted in their analysis. "The data is based on what is in the public domain and after speaking to government officials, especially in India," explained noted virologist Shahid Jameel. In November, Union Health Minister Harsh Vardhan said 400-500 million doses of COVID-19 vaccines were estimated to be made available for 250 to 300 million (25 crore to 30 crore) people in India by July-August 2021. Jameel told that all the vaccines 'pre-booked' by India are manufactured by Indian companies - Oxford-AstraZeneca and Novavax by Serum Institute of India (SII) in Pune and Sputnik V by Dr Reddy's Lab in Hyderabad. India's domestic vaccine candidate by Bharat Biotech also entered Phase 3 clinical trials this week. "Bharat Biotech and Zydus-Cadila would also add about 400 million doses annually. In brief, the numbers appear reasonable over 2021 and 2022," said Jameel, director of the Trivedi School of Biosciences, Ashoka University. "We can expect the first 250 million to be vaccinated in 2021; the remaining in the following years. The problem will not be vaccine doses, but the ability to deliver them," Jameel explained. He noted that 1.6 billion doses would cover 800 million people or 60 per cent of India's population. This, the virologist said, should be enough to develop herd immunity, a form of indirect protection from infectious disease that occurs when a sufficient percentage of a population has become immune to an infection. The first 500 million doses, the virologist said, are likely to go to 250 million people in the group that includes frontline workers, healthcare workers, sanitation, emergency services, and security services. This group also includes the elderly above 65 and patients with comorbidities. Immunologist Satyajit Rath said there is currently no particularly reliable estimate of the percentage of community coverage needed to be vaccinated in order to reach the point of 'herd immunity'. The reliability of models being used for these estimations is far from clear, he stressed. "Since all the vaccine candidates that are being discussed as purchased have two-dose vaccine regimens, the current number for India would vaccinate, at best, 80 crore (800 million) people. This, of course, does not account for logistical losses, which can be substantial," Rath, from <keyword id="9587667" type="COMPANY" weightage="20" keywordseo="the-national-institute-of-immunology">the National Institute of Immunology</keyword> (NII) in New Delhi, told . "Also, this seems to imply that COVID-19 vaccination is a one-time exercise. But it is not clear how long the vaccine-mediated protection will last, and therefore it is not clear when repeat vaccination will be needed, and how that will be delivered," he added. Flagging some uncertainties about the COVID dose purchases, Rath said he is "curious" about about the "confirmed" purchase by India. "Have these been paid for or at least committed to at a given price, are these acquisitions through the COVAX programme or independent of it, and most of all, of course, what is the delivery schedule agreed to in this acquisition, etc." Rath also noted that it is difficult to predict how many will be immunised, and when. "The next set of uncertainties I have is whether there are credible and well-worked out plans in India to match these delivery schedules with downstream transport, uptake and actual vaccination, plans for multi-stage transport, multi-point cold storage, provision of injection accessories... , the recording-keeping needed and most of all, the skilled personnel to administer the injections." In Rath's view, a certain sector of healthcare workers will likely be immunised in the next few months, as well as a certain proportion of 'first responder' people at high occupational risk of infection. "Beyond that, we are simply whistling in the wind at this stage," he said. The Duke analysis also found that Canada and the UK have each struck deals for over 350 million doses from seven developers. The analysis doesn't include Russia and China, both of which have their own vaccine programmes for their citizens. The researchers noted that a flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed. More than 10 candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorisation. The number of advance market commitments (AMCs) made by countries and multilateral partnerships eager to reserve vaccine supply, even before any candidates are on the market is unprecedented. "High-income countries currently hold a confirmed 3.8 billion doses, upper middle-income countries hold 829 million doses, and lower middle-income countries hold more than 1.7 billion doses," according to the report. The researchers said they have not been able to find evidence of any direct deals made by low-income countries, suggesting that such countries will be entirely reliant on the 20 per cent population coverage from COVAX. COVAX is a global initiative led by the WHO, the Coalition for Epidemic Preparedness Innovations (CEPI) and international vaccine alliance organization Gavi that aims to bring governments and vaccine manufacturers together to ensure all countries have access to COVID-19 vaccines once they become available. Since none of these vaccines are approved, Duke researchers said some of the purchased candidates may prove to be unsuccessful, adding countries that can afford to are purchasing a portfolio of vaccines, in hopes that one or more will get through the regulatory process. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-ril-airtel-indigo-spicejet-sbi-bank-of-baroda-vodafone-idea-granules-india-and-others/articleshow/79557810.cms">Top stocks to watch — RIL, Airtel, IndiGo, SpiceJet, SBI, Bank of Baroda, Vodafone-Idea, Granules India, and others</a> <a href="https://www.businessinsider.in/business/corporates/news/ultratech-cements-5477-crore-expansion-plan-is-a-sign-that-birla-is-betting-on-a-faster-economic-recovery/articleshow/79549626.cms">UltraTech Cement's ₹5,477 crore expansion plan is a sign that Birla is betting on a faster economic recovery</a> <a href="https://www.businessinsider.in/tech/news/sbis-mobile-banking-app-is-down-for-the-third-time-in-last-30-days/articleshow/79548953.cms">SBI’s mobile banking app is down for the third time in 30 days — digital services take a hit for the 25th time this year</a>

You Searched For "the gavi covax amc" and got 5 results

Serum Institute to manufacture 200 million doses of COVID-19 vaccine

IANS

Serum Institute to manufacture 200mn doses of Covid-19 vaccine

IANS

Serum Institute of India to produce 100 million doses of COVID-19 vaccine for less than ₹250 a dose

IANS

Unicef to lead global supply of Covid-19 vaccine

IANS

India largest buyer of COVID-19 vaccine with 1.6 billion doses, experts say this could cover 60% population

PTI

Popular Keywords

Buying Guides